Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts' expectations but showed a decline in U.S. revenue year over year.Here's how the company did:Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEGRevenue:  $994 million vs. $990 million expected by LSEGThe company's revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom's U.S. revenue declined 2% from $713.6 million the prior year. The company re ...

Exhibit 99.1 Dexcom Reports Third Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-October 24, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: 1 • Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic basis. • U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic basis, all on a year-o ...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from April 28, 2023 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company. According to the ...

DexCom, Inc. (DXCM) is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 10.26%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 23.03%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from ...

In its upcoming report, DexCom (DXCM) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 14% compared to the same period last year. Revenues are forecasted to be $991.55 million, representing a year-over-year increase of 1.7%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

Recent developments might have scared away some investors, but patience could pay off.Over the past five years, diabetes-focused medical device specialist DexCom (DXCM -0.50%) has made meaningful progress on several fronts. The company launched new products in the continuous glucose monitoring (CGM) niche and entered new geographies. Its revenue has generally increased at a good pace on a year-over-year basis.However, after a recent plunge, DexCom has underperformed the S&P 500 in the past half-decade. Can ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the DexCom class action lawsuit – captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.) – charges DexCom, Inc. (NASDAQ: DXCM) and certain of DexCom’s top executives with violations of the Securities Exchange Act of 1934. Subsequently filed complaints are captioned Oakland County Employees’ Retirement System v. DexCom, Inc., No. 24-cv-01804 (S.D. Cal.), and Carnes v. DexCom, Inc., No. 24-cv-01809 (S.D. Cal.). ...